TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Palvella Therapeutics
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved

Palvella Therapeutics reported positive Phase 2 trial results for QTORIN™ rapamycin gel in treating cutaneous venous malformations, with 73% of participants showing improvement and no serious adverse events reported.

Insights
MTEKW   positive

Company is expanding technological capabilities through strategic collaboration, gaining controlling interest in new venture, and positioning itself in innovative navigation technology market


PVLA   positive

Achieved statistically significant results in Phase 2 trial, demonstrated potential for first FDA-approved therapy for cutaneous venous malformations, and plans to pursue Breakthrough Therapy Designation